Tag Archives: ATLAS-ACS 2 TIMI 51

Tsimane people show healthiest arteries yet studied Indigenous South Americans from the Bolivian Amazon – the Tsimane people – have the lowest recorded levels of vascular ageing A South American Tsimane person of 80 years is estimated to have the same vascular age as an American person in their mid-50s, according to a study presented at the ACC. The Tsimane people – an indigenous forager-horticulturalist population of the Bolivian Amazon – have the lowest reported levels of vascular ageing for any population, with coronary atherosclerosis being five times less common than in the USA. This has led the researchers to propose that the lo

Bayer has announced that the oral anticoagulant, rivaroxaban, has reduced ischaemic events but increased bleeding in acute coronary syndrome (ACS) patients in the large-scale trial ATLAS-ACS 2 TIMI 51. The company said the drug was associated with a statistically significant reduction in the primary composite end point of cardiovascular death, myocardial infarction, and stroke versus placebo. However, it was also associated with a significant increase in the primary safety end point: major bleeding events not associated with coronary artery bypass surgery. Bayer says the results will be presented “as soon as possible at a forthcoming scient